Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Givinostat - Italfarmaco

Drug Profile

Givinostat - Italfarmaco

Alternative Names: ITF-2357

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Italfarmaco
  • Developer Italfarmaco; Radboud University
  • Class Amines; Antineoplastics; Carbamates; Hydroxamic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera; Juvenile rheumatoid arthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Duchenne muscular dystrophy
  • Phase II Myeloproliferative disorders
  • Phase I/II Polycythaemia vera
  • No development reported Hereditary autoinflammatory diseases; Juvenile rheumatoid arthritis
  • Discontinued Diffuse large B cell lymphoma; Hodgkin's disease; Multiple myeloma

Most Recent Events

  • 01 Aug 2019 Italfarmaco plans a phase III trial in Polycythaemia vera (PO)
  • 24 Jun 2018 Biomarkers information updated
  • 12 Dec 2017 Italfarmaco initiates enrolment in a phase II trial for Duchenne muscular dystrophy (Becker Muscular Dystrophy) in Italy (PO) (NCT03238235)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top